Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom

Regeneron stock toppled Thursday after the biotech giant reported lighter-than-expected sales of its new eye disease drug.

Investors Business Daily

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is expected to report its fiscal third-quarter earnings this month, and analysts project a single-digit profit plunge.

Barchart

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

Investors Business Daily

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Tesla led the S&P 500 index on Monday, moving toward a buy point. Regeneron Pharmaceuticals tumbled on a surprise court ruling.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.

Investors Business Daily

Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Barchart

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Barchart

Regeneron Pharma Tops Its Buy Zone Despite Mixed Sales For Blockbuster Eye Drug

Regeneron stock edged higher Thursday despite mixed results for its bread-and-butter eye-disease treatment franchise, Eylea.

Investors Business Daily

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

Barchart

Swing Trading Regeneron Stock Shows How To Bob And Weave

What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come. Here's how.

Investors Business Daily

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club

Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.

Barchart

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Investors Business Daily

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.

Top News

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron Pharmaceuticals surpasses expectations with strong fourth-quarter revenue, boosting investor confidence in the company's performance.

Investors Business Daily

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again

There's more than Eylea to like about Regeneron Pharmaceuticals right now, an analyst said Friday as REGN stock touched another record high.

Investors Business Daily

Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry

Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

67 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.